Current multiple myeloma (MM) therapies are largely non-curative with diminishing duration of response with each subsequent lines of therapy. With advances in research, future MM treatments are likely to provide better outcomes. The newer therapies include monoclonal antibodies in combination with novel agents, as well as the use of ADC, BiTE, and CAR-T cell therapy in early relapse. In the past month, we saw a few novel collaborations and compounds in China getting fast-tracked. This opens up more treatment approaches and a shorter time to market.